A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients

Inclusion Criteria: * Patients must have pathological or cytologically confirmed malignant melanoma with unresectable Stage III or Stage IV (including skin and distant lymph node metastasis M1a, lung metastasis M1b). * Patients who are resistant /refractory to approved therapies, or for whom no curative therapies are available. * Male or female, aged ≥18 and ≤70 years; ECOG performance status score of 0-2; Life expectancy of at least six months. * For women of childbearing potential, a negative pregnancy test within 7 days prior to the first treatment. * At least four weeks since prior other anti-tumor therapy, including endocrine, chemotherapy/radiotherapy and targeted therapy, at least six weeks since prior nitrosourea and mitomycin dosing, and have recovered from the adverse reactions due to prior therapy. * At least 4 weeks before prior surgery. * Must have one measurable or evaluable lesion according to RECIST 1.1 * With enough tumor tissues and diagnosed by the designated laboratory. * Body weight \>50kg. * Without functional disorder of major organs ( laboratory examination): Neutrophils≥1.5×10\^9/L, lymphocyte≥1.0×10\^9/L, PLT≥100×10\^9/L, Hb≥110g/L; BUN and Cr within normal range; TBIL≤1.5 times upper limit; ALT/AST≤2.5 times upper limit; PT/APTT within normal range. * Without obvious hereditary disease. * Must sign a written informed consent form prior to entering the study, with good compliance. Exclusion Criteria: * With extrapulmonary metastatic of melanoma, for instance, distant metastasis of liver, brain, bone, adrenal gland. * With serious internal disease, including serious heart disease, cerebral vascular disease, uncontrolled diabetes, uncontrolled hypertension, serious infections, active peptic ulcer, renal failure and respiratory failure. * Uncontrolled infectious diseases or other serious diseases, for example, HIV, Hepatitis B and Hepatitis C. * Uncontrolled brain metastases. * Lymphoma or leukemia patients. * Patients who have received bone marrow, stem cells or organ transplantation. * With immunodeficiency or autoimmune disease, leucoderma excluded. * Allergic constitution. * Chronic diseases needed immunosuppressive therapy or hormone therapy. * Patients treated with steroid hormone. * Unable to evaluate the immune status, or patients cannot comply with follow-up clinical evaluation. * Patients diagnosed with MDS (myelodysplastic syndromes). * Patients who are pregnant or breast-feeding. * Women (or patients' wife) of child-bearing without effective contraceptive measures. * Patients receiving any investigational drug or investigational treatment within 4 weeks prior to first dosing. * With uncontrolled mental disorders.